Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 5/20 | 0.72 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.72 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.72 |
| ▸ | ALK | Q9UM73 | 12/20 | 0.63 |
| ▸ | SPR | P35270 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270813 | 0.91 | MAP3K7 (0.74) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL10270581 | 0.90 | SPR (0.75) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL572281 | 0.90 | SPR (0.75) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL27907079 | 0.89 | MAP3K7 (0.71) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL14971480 | 0.88 | ALK (0.80) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL15200278 | 0.86 | ALK (0.81) | MAP3K7IRAK4IRAK1ALKSPR | |
| SCHEMBL21025707 | 0.86 | IRAK4 (0.87) | MAP3K7IRAK4IRAK1ALKMET | |
| SCHEMBL14619760 | 0.85 | IRAK4 (0.85) | MAP3K7IRAK4IRAK1ALKMET | |
| SCHEMBL13500601 | 0.85 | IRAK4 (0.85) | MAP3K7IRAK4IRAK1ALKMET | |
| SCHEMBL29313986 | 0.85 | IRAK4 (0.84) | MAP3K7IRAK4IRAK1ALKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |